Navigation Links
Benefits of higher oxygen, breathing device persist after infancy
Date:12/27/2012

vous system. These included cerebral palsy, blindness, hearing loss or low scores on tests of infant mental and motor development. The researchers selected this outcome because infants who died before 18 months of age could not be classified as having a neurodevelopmental impairment.

In terms of the primary outcome, the researchers found no differences between the groups.

When the researchers looked at outcome measures separately, however, they did observe differences. The researchers documented higher survival rates among children who received oxygen with higher saturation rates. The study's original findings showed that survivors in this group also had a greater risk of developing retinopathy of prematurity, an eye condition that can impair vision or cause blindness. Although those receiving higher oxygen levels were more likely to have had corrective eye surgery, by the time the children reached 18 to 22 months corrected age -- their age had they been born at the approximate time they were due. The researchers found that there was no difference in the rate of vision problems between the two groups.

"CPAP for infants has been available since the 1970s. This is the first study to compare surfactant treatment to CPAP in a large group of infants, and these results reassure us that CPAP is as good a choice in the first hour of life as traditional methods for very preterm babies who need help breathing," said senior author Rosemary D. Higgins, M.D., of the Pregnancy and Perinatology Branch of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), one of two NIH institutes supporting the study. "We've also confirmed that higher oxygen targets improve survival and don't appear to threaten survivors' vision in the longer term."

The study also received funding from the National Heart, Lung and Blood Institute.

Their findings appear in the New England Journal of Medicine.

<
'/>"/>
Contact: Robert Bock
bockr@mail.nih.gov
301-496-5133
NIH/National Institute of Child Health and Human Development
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Zane Benefits Posts Information & Videos on Defined Contribution Healthcare
2. Zane Benefits Publishes "The Crisis in Employee Health Benefits 1999-2012"
3. Robotic-assisted radical bladder surgery potentially benefits bladder cancer patients
4. Long-terms benefits follow brain surgery for certain forms of epilepsy
5. Shady Grove Eye and Vision Care Reminds Patients to Book Appointments Now Before 2012 Flex Benefits Run Out
6. Zane Benefits Publishes Information About Large Companies Switching to Defined Contribution & Private Exchanges for Employee Health Benefits
7. Zane Benefits Publishes Section 125 Premium Only Plan (POP) Reimbursable Health Insurance Premiums
8. Kentucky Social Security Disability Benefits Lawyer with The Frank Jenkins Law Office Voices Support for Recent Expansion of Compassionate Allowance Program
9. More signs of the benefits of marriage?
10. Zane Benefits Publishes 5-Step Defined Contribution Evaluation
11. Why Health Insurance Brokers Need An HRA Administration Partner: Zane Benefits Publishes Info
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2015)... March 29, 2015 At this ... platform provides basic health information around medical conditions ... discuss these challenges as well as helping them ... addresses six medical conditions using evidenced based information ... engage in conversations around them., ...
(Date:3/28/2015)... March 28, 2015 Rocket Pure , ... announced the release of their new natural sunscreen. They ... ounce packages. Both options come with a bonus lip ... RocketPure.com or on Amazon. Click to see the ... that the natural sunscreen is made with non-nano zinc oxide ...
(Date:3/28/2015)... 2015 With more than 4,500 ... of osteoporosis, osteoarthritis and musculoskeletal diseases gathered here ... be the first time in the 17-year history ... the hot-button topic is an emerging non-pharmaceutical protocol ... scientific principles of Wolff’s law, osteogenic loading at ...
(Date:3/28/2015)... New York, NY (PRWEB) March 28, 2015 ... 2015 highlighted a problem which could prove critical to ... Why system testing, a critical aspect of data security, ... payment card industry data security report, every major category ... vulnerability scanning and penetration testing. “With all the craziness ...
(Date:3/28/2015)... Delaying rotator cuff surgery on patients with ... presented today at the American Orthopaedic Society for Sports ... compared results for 170 patients who received rotator cuff ... capsule release procedure to relieve stiffness at the time ... from St. George Hospital in Sydney, Australia. “Both groups ...
Breaking Medicine News(10 mins):Health News:Krame Health Solutions Announces Release of AfroHealthLink, an Interactive Health Resource Center Tailored to Individuals of African & Caribbean Descent Around the World 2Health News:Krame Health Solutions Announces Release of AfroHealthLink, an Interactive Health Resource Center Tailored to Individuals of African & Caribbean Descent Around the World 3Health News:Rocket Pure Releases New Natural Sunscreens For Athletes 2Health News:Rocket Pure Releases New Natural Sunscreens For Athletes 3Health News:Non-Drug Protocol for Building Bone Density Expected to Steal Spotlight at World Congress on Osteoporosis 2Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 2Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 3Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 4Health News:No Need to Delay Rotator Cuff Surgery, Study Shows 2
... the past, it was thought that one of the selective ... the development of new behaviour to respond to the ecological ... a sudden reduction in food or the appearance of a ... and researcher at the Centre of Ecological Research and Forestry ...
... Today during the 88th General Session & Exhibition ... Barcelona, Spain, S. Offenbacher will present an abstract ... of Candidiasis-Associated Denture-Stomatitis." The goal of the ... in Candida albicans (a parasitic fungus that can ...
... of Orthopaedic Surgeons (AAOS) has approved and released an ... Joint Osteoarthritis." This major joint in the shoulder ... affected by osteoarthritis, causing pain, loss of function, and ... Rolando Izquierdo, MD, chair of the Academy work group ...
... By E.J. Mundell HealthDay Reporter , THURSDAY, ... Mary Cusack has been raising her son, Nicky, she,s become ... Nicky and others with autism often display. If left unchecked, ... and her husband, Tom, have found a solution to the ...
... conducting a clinical trial that targets malignant T-cell lymphoma, a ... affects the white blood cells that normally protect against illness, ... lymphomas are of B-cell origin, and 15% of T-cell origin. ... respond well to chemotherapy. Therefore, says Arthur ...
... Amanda Gardner HealthDay Reporter , WEDNESDAY, July 14 ... the risk of heart attack more than other medications of ... controls, a U.S. government advisory panel recommended late Wednesday. ... experts rejected the option that the U.S. Food and Drug ...
Cached Medicine News:Health News:The protective brain hypothesis is confirmed 2Health News:New research finds major activation themes in denture-stomatitis 2Health News:Shoulder arthritis? What patients need to know before treatment 2Health News:Shoulder arthritis? What patients need to know before treatment 3Health News:Gentle Horses Help Rein in Autism in Kids 2Health News:Gentle Horses Help Rein in Autism in Kids 3Health News:Gentle Horses Help Rein in Autism in Kids 4Health News:Avandia Raises Heart Risk But Should Stay on Market, FDA Panel Finds 2Health News:Avandia Raises Heart Risk But Should Stay on Market, FDA Panel Finds 3Health News:Avandia Raises Heart Risk But Should Stay on Market, FDA Panel Finds 4
(Date:3/27/2015)... , March 27, 2015 XRpro Sciences, ... drug discovery and development services which features high ... pharmaceutical industry, announced financial results for the year ... C.  Tyson, Chairman of XRpro Sciences commented, "We ... transition from development stage to commercial stage in ...
(Date:3/27/2015)... March 27, 2015  Valeant Pharmaceuticals International, Inc. (NYSE: ... of its previously announced registered offering of common shares ... "Offering"). Pursuant to the Offering, the Company issued 7,286,432 ... for aggregate gross proceeds of approximately $1.45 billion. On ... Securities and Exchange Commission a final prospectus supplement to ...
(Date:3/27/2015)... , March 27, 2015 The International Myeloma ... myeloma patients while working toward prevention and a cure ... for introducing a federal resolution (H. Res. 174) that ... as "National Multiple Myeloma Awareness Month." Currently ... worldwide, and more than 110,000 new cases are diagnosed ...
Breaking Medicine Technology:XRpro Sciences Announces Fiscal 2014 Financial Results 2XRpro Sciences Announces Fiscal 2014 Financial Results 3XRpro Sciences Announces Fiscal 2014 Financial Results 4Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 2Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 3The International Myeloma Foundation (IMF) Secures the Introduction of a Federal Resolution Recognizing March 2015 as "National Multiple Myeloma Awareness Month" 2
... Nov. 4 CVS Caremark (NYSE: CVS ) ... position of SVP, Marketing for its pharmacy benefit management ... marketing from Jack Bruner, who is transitioning to the ... http://www.newscom.com/cgi-bin/prnh/20090226/NE75914LOGO ) , Greer brings ...
... 4 Neuronascent, Inc., a privately-held biotechnology company ... of depression, Alzheimer,s disease, Parkinson,s and other neurodegenerative ... agreement with ChemRar Pharma, a Russian biotechnology start-up ... and stem cells to treat cancer. Under the ...
Cached Medicine Technology:Company Appoints New SVP, Marketing for PBM Business 2Neuronascent Announces Collaboration with ChemRar for Characterization of Developmental Pathway Inhibitors Using Neuronascent's Neurogenesis Platform 2
... Analyzer II is a ... to enumerate fluorescently labeled ... selected and aligned. The ... CellTracks® Analyzer II, a ...
... These unique Acid Fast ... sputum smear with appropriate background ... containing a positive and negative ... Kinyoun (Cat. No. 353), Ziehl-Neelsen ...
PRINCIPLE: The QC-SLIDES™ are specifically designed microscope slides intended to be part of the quality control program to monitor microbiological stains and staining techniques....
PRINCIPLE: The QC-SLIDES™ are specifically designed microscope slides intended to be part of the quality control program to monitor microbiological stains and staining techniques....
Medicine Products: